Virion Biotherapeutics’ purpose is to develop the first rapid-acting, broad-spectrum therapeutic to treat the full range of viral respiratory diseases irrespective of the viruses that cause them, from the most acute infections to the common cold. We have shown this to be possible with our lead agent VH244 in highly-translatable in vivo preclinical models. Virion’s transformative approach is enabled by a unique RNA-based technology platform, extensive drug discovery and development expertise, and a leadership team committed to changing the treatment paradigm. Our success will be to minimize infectious-disease-related suffering as well as alleviate an enormous economic burden worldwide.
